

**Zacks Sell List Highlights: Andrx, Adams Respiratory, ADTRAN and Daktronics**

1,008 words

7 September 2006

06:00

Business Wire

BWR

English

(c) 2006 Business Wire. All Rights Reserved.

CHICAGO - (BUSINESS WIRE) - Sept. 7, 2006 - Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Andrx Corp. (NASDAQ:ADRX) and Adams Respiratory Therapeutics Inc. (NASDAQ:ARXT). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: ADTRAN Inc. (NASDAQ:ADTN) and Daktronics Inc. (NASDAQ:DAKT). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: <http://at.zacks.com/?id=92>.

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List -- Stocks to Sell Now by 129.7% annually (11.9% vs. 5.2% respectively). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why ADRX and ARXT have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

Andrx Corp. (NASDAQ:ADRX) has seen this year's earnings estimates drop 28 cents per share over the past two months. Next year's estimates have dropped 17 cents per share. Andrx reported second-quarter profits fell 82% from last year. The company has missed earnings estimates in each of the past four quarters. The company is in the process of merging with Watson Pharmaceuticals.

Adams Respiratory Therapeutics Inc. (NASDAQ:ARXT) has experienced a drop in analyst estimates. Earnings estimates for this year stand at \$1.80 per share, down 14 cents from 30 days ago. The stock fell last month after the company said an unnamed drug maker claimed to have filed an abbreviated new drug application to the Food and Drug Administration for a competitor to Adams' Mucinex expectorant.

Here is a synopsis of why ADTN and DAKT have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks:

ADTRAN Inc. (NASDAQ:ADTN) has been the target of increasing bearishness by analysts. Over the past two months, full year estimates have declined over 12%. The new consensus estimate calls for \$1.16 per share this year. The company missed second-quarter estimates by a penny and guided lower for the third quarter as well. Current estimates call for 33 cents per share, down from 41 cents two months ago.

Daktronics Inc. (NASDAQ:DAKT) has seen its earnings estimates drop for this year. The current year's consensus estimate of 60 cents per share is 10 cents below the forecast of two months ago. The company missed fiscal first-quarter earnings estimates by 29%. Gross margins have been hurt at the company recently.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions" is available to provide this insightful background. Download a free copy now to prosper in the years to come at <http://at.zacks.com/?id=93>

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." A \$10,000 investment in the Zacks Rank list made in 1988 would now be worth \$1.8 million - equivalent to a 32.4% annualized return! During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8%, while the S&P 500 tumbled 37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 145.8% annually (+4.7% vs. +11.6%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks #1 Rank stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting <http://at.zacks.com/?id=94>.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at <http://at.zacks.com/?id=95>.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Document BWR0000020060907e2970028q

Search Summary

Text	
Date	All Dates
Source	PR Newswire (U.S.) Or GlobeNewswire (U.S.) Or Business Wire (U.S.) Not Newswires
Author	All Authors
Company	Adtran Inc
Subject	All Subjects
Industry	All Industries
Region	United States
Language	English
Results Found	809
Timestamp	18 July 2018 12:52